Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06251115
Status:
RECRUITING
Last Update Posted:
2024-04-26
First Post:
2024-02-01
Brief Title:
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
Sponsor:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The vast majority of liver cancers have an insidious onset and are often asymptomatic in the early stages making early diagnosis difficult Once diagnosed most liver cancers have reached locally advanced stages or distant metastases equivalent to Barcelona stage BCLC C-D The tumors progress rapidly and there is a lack of effective treatments The survival period of cancer patients is generally only 3-6 months Cellular immunotherapy including CAR-T and TCR-T is considered a new hope for the treatment of cancer
The purpose of this study is to explore the safety of QY-1-T a TCR-T targeting HBV in the treatment of HBV-related liver cancer and to preliminarily evaluate the efficacy of QY-1-T in patients with HBV-related advanced liver cancer
The purpose of this study is to explore the safety of QY-1-T a TCR-T targeting HBV in the treatment of HBV-related liver cancer and to preliminarily evaluate the efficacy of QY-1-T in patients with HBV-related advanced liver cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None